Ventral tegmental lesions reduce overconsumption of normally preferred taste fluid in rats.
Previous studies have suggested that the brain regions along the taste pathway and its anatomical interfacing with the brain reward system are concerned with palatability-induced consumption. To clarify whether the ventral tegmental area (VTA) is involved in the behavioral expression induced by taste pleasantness, we examined the effects of lesions to the VTA on the consumption of taste stimuli in rats. (1) Bilateral extensive electrolytic lesions to the VTA selectively reduced the consumption of a normally preferred taste fluid (0.1 M sucrose) compared to that of sham-operated animals during a 24-h two-bottle choice test. The consumption of other fluids, including non-preferred taste fluids (HCl and quinine hydrochloride) was not different between the lesioned and sham animals. (2) The injection of midazolam (3 mg/kg), a benzodiazepine agonist, or morphine (2 mg/kg) significantly increased the consumption of 0.1 M sucrose fluids in the sham animals. The same injections, however, failed to increase intake of the 0.1 M sucrose in rats with 6-hydroxydopamine lesions of the VTA. Neither midazolam nor morphine modified the intake of non-preferred quinine (0.0003 M) solution in both the lesioned and sham animals. These results suggest that dopaminergic mediation in the VTA is required to enhance the consumption of normally preferred fluids exclusively.
Laboratory of Behavioral Physiology, Graduate School of Human Sciences, Osaka University, 1-2 Yamadaoka, Suita, Osaka 565-0871, Japan. shimura@hus.osaka-u.ac.jp
Tsuyoshi
T
Shimura
Yoko
Y
Kamada
Takashi
T
Yamamoto
D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004327:Drinking Behavior / Q000502:physiology*; D006851:Hydrochloric Acid / Q000494:pharmacology; D007150:Immunohistochemistry; D008297:Male; D008874:Midazolam / Q000494:pharmacology; D009020:Morphine / Q000008:administration & dosage / Q000494:pharmacology; D009294:Narcotics / Q000008:administration & dosage / Q000494:pharmacology; D016627:Oxidopamine; D011803:Quinine / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D012965:Sodium Chloride / Q000494:pharmacology; D013238:Stereotaxic Techniques; D013395:Sucrose / Q000494:pharmacology; D013563:Sympathectomy, Chemical; D013649:Taste / Q000502:physiology*; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism / Q000502:physiology; D017557:Ventral Tegmental Area / Q000502:physiology*
D014151:Anti-Anxiety Agents; D009294:Narcotics; D012965:Sodium Chloride; D013395:Sucrose; D009020:Morphine; D016627:Oxidopamine; D011803:Quinine; D014446:Tyrosine 3-Monooxygenase; D006851:Hydrochloric Acid; D008874:Midazolam